デフィブリレーション後のブラジアリズムと血液動力学的うつ病における内生アデノシンの役割
1Department of Medicine, University of Virginia Medical Center, Charlottesville.
Circulation
|July 1, 1989
まとめ
アデノシンアンタゴニストであるBW-A1433Uは,除細動後のブラディアルリズムと血液動力学的うつ病を効果的に予防し,逆転させます. これは,内生アデノシンがデフィブリレーション後の心血管崩壊において重要な役割を果たしていることを示唆している.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
背景:
- デフィブリレーション後のブラジアリズムと血液動力学的うつ病は,重要な臨床上の懸念事項である.
- アデノシンは,デフィブリレーション後の心血管崩壊の媒介者として関与しています.
研究 の 目的:
- 豚のモデルにおいて,アデノシン・アンタゴニストBW-A1433Uが,デフィブリレーション後のブラジアリズムと血液動力学的うつ病に及ぼす影響を調査する.
- アデノシンの効果を阻害することで,除細動後の不良心血管イベントを軽減できるかどうかを判断する.
主な方法:
- ハロタン・窒素酸化物で麻酔した豚に2つのプロトコルを使用した.
- プロトコル1:BW-A1433U (5 mg/kgIV) の投与前および後に心房細動エピソード (15秒) が誘発されました.
- プロトコル2:BW-A1433Uの効果は,ディピリダモール (核酸吸収阻害剤) とメトキサミン (低血圧に対抗する) で評価されました.
主要な成果:
- BW-A1433Uは,心房閉塞後のデフィブリレーションの発生率 (6%対47%) を有意に減少させました.
- BW-A1433Uの投与は,メトキサミンとディピリダモール単独投与と比較して,自発的な心拍数と血圧を増加させた.
- BW-A1433Uは,ディピリダモール誘発のうつ病の間,心拍数と血圧を迅速に回復させた.
結論:
- BW-A1433Uは,デフィブリレーション後のブラジアリズムと血液動力学的うつ病を効果的に逆転させ,予防します.
- 内生アデノシンは,デフィブリレーション後の心血管崩壊の重要な媒介者である可能性が高い.
- アデノシン・アンタゴニズムは,デフィブリレーション後の合併症の管理のための潜在的な治療戦略です.
関連する概念動画
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:18Dysrhythmias IV: Characteristics of Bradyarrhythmias
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...